McLean LS - Search Results

1

Optimising Patient Outcomes in Tongue Cancer: A Multidisciplinary Approach.

de Boer J, Barnett R, Cardin A, Cimoli M, Davies L, Delany C, Dixon BJ, Evans SM, Findlay MW, Fox C, Ftanou M, Hart CD, Howard M, Iseli TA, Jackson A, Kranz S, Le BH, Lekgabe E, Lennox R, McLean LS, Neeson PJ, Ng SP, O'Reilly LA, Ramakrishnan A, Rowe D, Service C, Singh A, Thai AA, Tiong A, Yap T, Wiesenfeld D. de Boer J, et al. Among authors: mclean ls. Cancers (Basel). 2024 Mar 26;16(7):1277. doi: 10.3390/cancers16071277. Cancers (Basel). 2024. PMID: 38610956 Free PMC article. Review.

2

FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma.

McLean LS, Cavanagh K, Hicks RJ, Callahan J, Xie J, Cardin A, Lim AM, Rischin D. McLean LS, et al. Cancer Imaging. 2021 Oct 13;21(1):57. doi: 10.1186/s40644-021-00426-2. Cancer Imaging. 2021. PMID: 34645517 Free PMC article.

3

Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma.

McLean LS, Lim AM, Webb A, Cavanagh K, Thai A, Magarey M, Fox C, Kleid S, Rischin D. McLean LS, et al. Front Oncol. 2022 Jan 18;11:796197. doi: 10.3389/fonc.2021.796197. eCollection 2021. Front Oncol. 2022. PMID: 35117997 Free PMC article.

4

Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma.

McLean LS, Lim AM, Bressel M, Thai AA, Rischin D. McLean LS, et al. Drugs Aging. 2024 Mar;41(3):271-281. doi: 10.1007/s40266-024-01095-z. Epub 2024 Mar 6. Drugs Aging. 2024. PMID: 38446342 Free PMC article.

5

Assessment of perineural spread in advanced cutaneous squamous cell carcinomas treated with immunotherapy.

Cavanagh K, McLean LS, Lim AM, Cardin A, Levy SM, Rischin D. Cavanagh K, et al. Among authors: mclean ls. Cancer Imaging. 2024 Mar 18;24(1):37. doi: 10.1186/s40644-024-00678-8. Cancer Imaging. 2024. PMID: 38500235 Free PMC article.

6

A Retrospective Review and Comprehensive Tumour Profiling of Advanced Non-Melanomatous Cutaneous Spindle Cell Neoplasms Treated with Immune-Checkpoint Inhibitors.

McLean LS, Lim AM, Angel C, Young RJ, Pizzolla A, Archer S, Solomon BJ, Thai AA, Lewin J, Rischin D. McLean LS, et al. Cancers (Basel). 2024 Apr 10;16(8):1452. doi: 10.3390/cancers16081452. Cancers (Basel). 2024. PMID: 38672534 Free PMC article.

7

Immunotherapy in oncogene addicted non-small cell lung cancer.

McLean L, Leal JL, Solomon BJ, John T. McLean L, et al. Transl Lung Cancer Res. 2021 Jun;10(6):2736-2751. doi: 10.21037/tlcr-20-772. Transl Lung Cancer Res. 2021. PMID: 34295674 Free PMC article. Review.

8

In-transit cutaneous squamous cell carcinoma.

McLean LS, Rischin D. McLean LS, et al. Med J Aust. 2022 May 2;216(8):401. doi: 10.5694/mja2.51486. Epub 2022 Mar 30. Med J Aust. 2022. PMID: 35355269 No abstract available.

9

A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.

McLean LS, Morris TA, Gramza A, Liu S, Khan SA, Colevas AD, Pearce T, Rischin D. McLean LS, et al. Invest New Drugs. 2022 Aug;40(4):782-788. doi: 10.1007/s10637-022-01230-w. Epub 2022 Apr 18. Invest New Drugs. 2022. PMID: 35435625 Clinical Trial.

10

Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab.

Zhong YY, McLean L, Buckle A, Siva S, Tran B. Zhong YY, et al. Can J Urol. 2020 Aug;27(4):10339-10341. Can J Urol. 2020. PMID: 32861263

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters